BioSpace News Archive

Drug Development

UPDATE -- Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

Rain Therapeutics Inc. announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53.

August 4, 2022
·
6 min read
Operating Room Integration Systems Market Size Worth USD 3,104.4 Million by 2027 | Emergen Research

According to a recent analysis by Emergen Research, the operating room integration systems market would generate USD 3,104.4 million by 2027.

August 4, 2022
·
7 min read
Cancer Monoclonal Antibodies Market Size USD 159.96 BN by 2030

According to Vision Research Reports, the global cancer monoclonal antibodies market size is expected to hit around USD 159.96 billion by 2030, growing at a CAGR of 11.07% from 2022 to 2030.

August 4, 2022
·
7 min read
mRNA Therapeutics Market Size to Reach USD 37.89 BN by 2030

According to Report Study, the global mRNA therapeutics market was valued at USD 33 billion in 2021 and it is predicted to surpass around USD 37.89 billion by 2030 with a CAGR of 1.55% from 2022 to 2030

August 4, 2022
·
9 min read
U.S. Tendon Repair Market Size to Reach USD 1.6 BN by 2030

According to Report Study, the U.S. tendon repair market was valued at USD 821.3 million in 2021 and it is predicted to surpass around USD 1.6 billion by 2030 with a CAGR of 7.69% from 2022 to 2030

August 4, 2022
·
6 min read
Biotech Bay

Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022

Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022.

August 4, 2022
·
1 min read
Business

Edgewise Therapeutics Reports Second Quarter 2022 Financial Results

Edgewise Therapeutics, Inc. today reported financial results for the second quarter of 2022 and recent business highlights.

August 4, 2022
·
11 min read
Business

Paragon 28 Announces Changes to its Board of Directors

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced two changes to the composition of its Board of Directors.

August 4, 2022
·
2 min read
Business

Xentria Appoints Lead Scientific Advisor and Chief Operating Officer

Xentria Inc., a biotech company focused on developing novel therapeutics to address unmet clinical needs, made key leadership appointments, naming Dr. Robert Baughman as Lead Scientific Advisor and Kirsten Anderson as Chief Operating Officer.

August 4, 2022
·
4 min read
Deals

Avinger Announces $5 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

Avinger, Inc. today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the sale and issuance of 1,484,019 shares of the Company’s common stock.

August 4, 2022
·
7 min read